NASDAQ: CNTBConnect Biopharma Holdings Ltd Stock
$1.58+0.04 (+2.6%)
Updated Oct 29, 2025
CNTB Price
$1.58
Fair Value Price
N/A
Market Cap
$88.21M
52 Week Low
$0.51
52 Week High
$2.86
P/E
-1.88x
P/B
1.24x
P/S
27.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.97M
Earnings
-$46.45M
Gross Margin
100%
Operating Margin
-2,350.43%
Profit Margin
-2,363.8%
Debt to Equity
0.16
Operating Cash Flow
-$36M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNTB Overview
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company developing immune modulators for the treatment of serious autoimmune diseases and inflammation. Its lead candidates are CBP-201, a treatment for inflammatory allergic diseases (atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps), CBP-307, for the treatment of autoimmune-related inflammation diseases, CBP-174 to treat chronic itch associated with skin inflammation, and CBP-233 to treat T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNTB's potential to beat the market
- CNTB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNTB
RankedUnranked of 488
RankedUnranked of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.17 | A | |
| $12.22 | A | |
| $7.19 | A |
Be the first to know about important CNTB news, forecast changes, insider trades & much more!
CNTB News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNTB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNTB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CNTB is good value based on its book value relative to its share price (1.24x), compared to the US Biotechnology industry average (4.96x)
P/B vs Industry Valuation
CNTB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CNTB due diligence checks available for Premium users.
Valuation
CNTB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.88x
Industry
-90.6x
Market
41.57x
CNTB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.24x
Industry
4.96x
CNTB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNTB's financial health
Profit margin
Revenue
$48.0k
Net Income
-$12.9M
Profit Margin
-26,872.9%
CNTB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CNTB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$82.7M
Liabilities
$11.4M
Debt to equity
0.16
CNTB's short-term assets ($77.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNTB's short-term assets ($77.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNTB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.6M
Investing
$5.1M
Financing
$161.0k
CNTB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNTB vs Biotech Stocks
Connect Biopharma Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.